Investigational Drug Information for NRX-101
✉ Email this page to a colleague
What is the development status for investigational drug NRX-101?
NRX-101 is an investigational drug.
There have been 7 clinical trials for NRX-101.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Bipolar Disorder. The leading clinical trial sponsors are NeuroRx, Inc., Target Health Inc., and Bracket, Inc.
There are ten US patents protecting this investigational drug and five hundred and seventy-seven international patents.
Summary for NRX-101
| US Patents | 10 |
| International Patents | 577 |
| US Patent Applications | 91 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 2 (2019-06-25) |
| Vendors | 11 |
Recent Clinical Trials for NRX-101
| Title | Sponsor | Phase |
|---|---|---|
| NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis | NeuroRx, Inc. | Phase 2 |
| NRX101 for Moderate Bipolar Depression and Suicidal Ideation | Bracket, Inc. | Phase 2/Phase 3 |
| NRX101 for Moderate Bipolar Depression and Suicidal Ideation | Statistics Collaborative, Inc. | Phase 2/Phase 3 |
Clinical Trial Summary for NRX-101
Top disease conditions for NRX-101
Top clinical trial sponsors for NRX-101
US Patents for NRX-101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| NRX-101 | ⤷ Sign Up | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | Chase Pharmaceuticals Corporation (Washington, DC) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Watson Pharmaceuticals, Inc. (Corona, CA) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for transdermal oxybutynin therapy | Watson Laboratories, Inc. (Salt Lake City, UT) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Watson Laboratories, Inc. (Salt Lake City, UT) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Watson Laboratories, Inc. (Salt Lake City, UT) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Watson Laboratories, Inc. (Salt Lake City, UT) | ⤷ Sign Up |
| NRX-101 | ⤷ Sign Up | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Watson Laboratories, Inc. (Salt Lake City, UT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for NRX-101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| NRX-101 | Canada | CA2973372 | 2035-01-09 | ⤷ Sign Up |
| NRX-101 | European Patent Office | EP3242659 | 2035-01-09 | ⤷ Sign Up |
| NRX-101 | European Patent Office | EP4122460 | 2035-01-09 | ⤷ Sign Up |
| NRX-101 | World Intellectual Property Organization (WIPO) | WO2016112263 | 2035-01-09 | ⤷ Sign Up |
| NRX-101 | Canada | CA2978214 | 2035-03-06 | ⤷ Sign Up |
| NRX-101 | Canada | CA2996717 | 2035-03-06 | ⤷ Sign Up |
| NRX-101 | Canada | CA2996719 | 2035-03-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
